Get the Stockscreener App
28.50
3.51%
0.9827
Roivant Sciences Ltd stock is traded at $28.50, with a volume of 1.19M.
It is up +3.51% in the last 24 hours and up +7.86% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$27.52
Open:
$27.93
24h Volume:
1.19M
Relative Volume:
0.20
Market Cap:
$20.39B
Revenue:
$13.31M
Net Income/Loss:
$-1.01B
P/E Ratio:
-24.39
EPS:
-1.1685
Net Cash Flow:
$-766.86M
1W Performance:
+1.23%
1M Performance:
+7.86%
6M Performance:
+45.48%
1Y Performance:
+145.14%
1-Day Range:
$27.89
$28.55
1-Week Range:
$27.06
$28.58
52-Week Range:
$10.58
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.49 | 19.88B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
429.46 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
705.33 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
780.07 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.58 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.34 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake - Insider Monkey
Roivant Sciences: Moderna Settlement, Brepocitinib Support A Long-Term Buy (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 30% Upside in Healthcare Biotech - DirectorsTalk Interviews
Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Roivant Sciences Ltd. $ROIV Stake Cut by Impax Asset Management Group plc - MarketBeat
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility - simplywall.st
M&T Bank Corp Takes Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Montes Archimedes Acquisition (ROIV) upgraded to buy: Here's what you should know - MSN
Citigroup Maintains Roivant Sciences (ROIV) Buy Recommendation - MSN
Price-Driven Insight from (ROIV) for Rule-Based Strategy - Stock Traders Daily
Roivant Sciences Insider Sold Shares Worth $5,918,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Roivant Sciences(ROIV.US) Officer Sells US$5.92 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president exercises 200K options, sells shares - Stock Titan
Roivant Sciences (ROIV) CFO awarded 60,644 RSUs and 84,026 stock options - Stock Titan
Roivant Sciences (ROIV) grants CAO new RSUs and stock options - Stock Titan
Roivant Sciences (ROIV) director gets share award, settles taxes in stock - Stock Titan
Roivant Sciences (ROIV) director gets fully vested 670-share award - Stock Titan
Roivant Sciences (ROIV) director gets share grant with tax netting - Stock Titan
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Roivant Sciences Insider Sold Shares Worth $8,449,810, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (ROIV) CEO sells 289,774 shares around $29 - Stock Titan
Roivant (ROIV) Stock Insider Ownership (Smart Money Outflows) 2026-04-20Shared Trade Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat - MSN
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $35 - Moomoo
ROIV Maintained by Piper Sandler -- Price Target Raised to $40 - GuruFocus
Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 8.45 Million in Common Stocks - Moomoo
Matthew Gline sells $8.44M in ROIV stock (ROIV) — insider Form 144 filing - Stock Titan
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Piper Sandler Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $40 - Moomoo
Consolidated Portfolio Review Corp Acquires Shares of 276,530 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure - Insider Monkey
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Goldman Sachs Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
10 Must-Buy US Stocks to Buy Right Now - Insider Monkey
A Look At Roivant Sciences (ROIV) Valuation As Analyst Upgrades And Brepocitinib Progress Lift Sentiment - simplywall.st
(ROIV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value! - Smartkarma
Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)? - simplywall.st
Insider Sell Alert: Jennifer Humes Sells Shares of Roivant Scien - GuruFocus
Montes Archimedes Acquisition (ROIV) Raised to Buy: Key Information You Need - Bitget
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CAO Sells 13,538 Shares of Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX) - The Globe and Mail
What happens to Roivant (ROIV) Stock after earnings | Price at $28.44, Up 0.96%Stock Analysis - Xã Thanh Hà
Roivant Sciences Ltd. (ROIV) Stock forecasts - Yahoo Finance UK
Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Apr 20 '26 |
Sale |
29.59 |
200,000 |
5,918,000 |
1,647,546 |
| Gline Matthew | CEO |
Apr 16 '26 |
Sale |
29.16 |
289,774 |
8,449,810 |
16,736,116 |
1.70%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):